Piper Jaffray analyst Christopher Raymond noted that the FDA approved Crysvita and gave the treatment an indication for both pediatric and adult XLH patients, which is "notably broader" than the EU label that only includes pediatric patients. Raymond, who assumes pricing of $150K/patient/year for adults and $100K/patient/year for pediatric patients, forecasts Crysvita revenue from North America growing from $9M in 2018 to $336M in 2022. The analyst remains a buyer of Ultragenyx shares, noting the company now has two drugs approved in the U.S. and additional catalysts coming during 2018.